Loading organizations...
§ Private Profile · 150 Chestnut Street, Providence, RI 02903
Minimally invasive solutions for natural bone healing in spinal fractures.
Lenoss Medical develops advanced biologic, cementless technology designed for the physiological treatment of osteoporotic spinal column fractures. Their core product, OsteoPearl, provides a novel approach to stabilize damaged vertebrae by leveraging the body's natural healing processes, moving beyond conventional cement-based solutions. This innovative method aims to facilitate authentic bone repair, offering a more integrated and biological solution for spinal health.
Dom Messerli, the founder, President, and CEO of Lenoss Medical, established the company driven by a deep understanding of spinal disease complexities and a commitment to more physiological treatment pathways. Messerli brings extensive experience from his tenure as Director of R&D at Johnson & Johnson's DePuy Synthes Spine, where he significantly contributed to product development and market leadership. His background as an inventor in medical devices underscores his technical and leadership pedigree.
The company's product caters to patients suffering from osteoporotic spinal fractures, offering an alternative that supports natural bone regeneration and stabilization. Lenoss Medical’s overarching vision is to pioneer and advance physiological treatment options for spinal conditions, emphasizing solutions that harmonize with the body's intrinsic healing capabilities to improve long-term patient outcomes.
Lenoss Medical has raised $10.0M across 2 funding rounds.
Lenoss Medical has raised $10.0M in total across 2 funding rounds.
Lenoss Medical is a Providence, RI-based biomedical startup developing the OsteoPearl VBA System, a fully biologic, cementless implant for treating vertebral compression fractures (VCFs) in osteoporotic patients.[1][2][5] The product consists of 100% allograft cortical bone "pearls" linked flexibly to form a 3D structural matrix that provides immediate stability, osteoinductive and osteoconductive properties for new bone growth, and long-term healing without cement-related risks like leakage or embolisms.[1][2][3] It serves spine surgeons and osteoporosis patients, solving the limitations of traditional kyphoplasty—such as lack of bone formation and cement migration complications affecting 1 in 5 procedures—via a streamlined, minimally invasive outpatient procedure.[1][2] The company has achieved commercial use, completed nearly 50 surgeries without embolisms, raised $1.3M in seed funding, and secured 23 patents as of September 2025.[3][5][8]
Lenoss Medical was founded by Dom Messerli, its visionary President and CEO, who invented the OsteoPearl technology while working at Johnson & Johnson (J&J) as Director of R&D for DePuy Synthes Spine.[3][6] Messerli, with prior leadership in product development and marketing that grew Synthes Spine to over $500M in revenue, licensed the innovation from J&J after persistent negotiations.[3][6] Motivated by the need for natural bone repair over "epoxy-like" cement in VCF treatments, he assembled a team of industry professionals and clinical advisors.[1][6] Key early milestones include securing an exclusive worldwide license from J&J, partnering with MTF Biologics for tissue supply, patenting surgical instruments like the Elevoss Cavity Creator, performing the first in-human surgery, and reaching nearly 50 procedures.[3] The company raised $1.3M in seed funding to launch, marking its shift from concept to commercialization.[8]
Lenoss rides the trend toward biologic and regenerative therapies in spine care, shifting from synthetic cements to natural scaffolds amid rising osteoporosis cases and demand for minimally invasive solutions (MIS).[1][2][4][7] Timing aligns with advances in ultra-MIS, awake TLIF, and endoscopic techniques, where OsteoPearl addresses unmet needs like maximal graft size in tissue-sparing procedures.[7] Market forces favoring it include cement kyphoplasty's high complication rates (e.g., pulmonary hypertension in fragile patients) and biologics' standard-of-care status in spinal pathologies.[1][4] By enabling physiological repair, Lenoss influences the ecosystem, challenging the "osseous healing paradigm" and potentially expanding to areas like OsteoLif for underrepresented MIS applications.[7][8]
Lenoss is poised for scaled commercialization, leveraging its 23-patent fortress, biologic edge, and embolism-free track record to capture VCF market share and explore MIS expansions like OsteoLif.[3][5][7] Trends in biologics, outpatient MIS, and patient-centered innovation will propel growth, with strategic partnerships (e.g., MTF Biologics) aiding global reach.[3][5] Its influence may evolve by redefining VCF standards, reducing cement risks, and inspiring natural-healing tech—placing "natural bone where new bone is needed most," as its mission promises.[1][4]
Lenoss Medical has raised $10.0M across 2 funding rounds. Most recently, it raised $6.0M Other Equity in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 17, 2026 | $6M Venture Round | — | James Goulka, Beacon Angels, Highpoint Ventures, Magpie Neurosurgical Innovation Venture Fund, Thorne Sparkman, Xcellerant Ventures | Announced |
| Dec 1, 2023 | $4M Series A | — | Xcellerant Ventures, Highpoint Ventures, Righthill Ventures, Vodia Ventures | Announced |
Lenoss Medical has raised $10.0M in total across 2 funding rounds.
Lenoss Medical's investors include James Goulka, Beacon Angels, Highpoint Ventures, Magpie Neurosurgical Innovation Venture Fund, Thorne Sparkman, Xcellerant Ventures, RightHill Ventures, Vodia Ventures.